Efficient vaccine against pandemic influenza: Combining DNA vaccination and targeted delivery to MHC class II molecules

Expert Review of Vaccines

Volumn 14, Issue 6, 2015, Pages 805-814

  Grødeland, Gunnveig ^a,b,c   Bogen, Bjarne ^a,b,c  

^a UNIVERSITY OF OSLO   (Norway)

^b KG Jebsen Centre for Research on Influenza Vaccines   (Norway)

^c OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

antibodies; APC targeting; DNA vaccine; influenza; MHC II molecules; vaccine

Indexed keywords

ANTIBODY; DNA VACCINE; HEMAGGLUTININ; INFLUENZA VACCINE; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; HLA ANTIGEN CLASS 2; INFLUENZA VIRUS HEMAGGLUTININ; VIRUS ANTIBODY; VIRUS ANTIGEN;

ANTIGEN PRESENTING CELL; DNA IMMUNIZATION; GENE TARGETING; HUMAN; INFLUENZA VIRUS A H1N1; MEXICAN SWINE FLU CAL07 VIRUS; NONHUMAN; PANDEMIC INFLUENZA; PRIORITY JOURNAL; REVIEW; SWINE INFLUENZA VIRUS; ANIMAL; BLOOD; DRUG DEVELOPMENT; GENETICS; IMMUNOLOGY; INFLUENZA, HUMAN; ISOLATION AND PURIFICATION; METABOLISM; PANDEMICS; PHARMACEUTICS; PROCEDURES; T LYMPHOCYTE; TRENDS; VACCINATION;

ANIMALS; ANTIBODIES, VIRAL; ANTIGENS, VIRAL; DRUG DISCOVERY; HEMAGGLUTININ GLYCOPROTEINS, INFLUENZA VIRUS; HISTOCOMPATIBILITY ANTIGENS CLASS II; HUMANS; INFLUENZA VACCINES; INFLUENZA, HUMAN; PANDEMICS; T-LYMPHOCYTES; TECHNOLOGY, PHARMACEUTICAL; VACCINATION; VACCINES, DNA;

EID: 84929332719     PISSN: 14760584     EISSN: 17448395     Source Type: Journal    
DOI: 10.1586/14760584.2015.1029919     Document Type: Review

References (88)

1. Wolff JA, Malone RW, Williams P, et al. Direct gene transfer into mouse muscle in vivo. Science 1990;247:1465-8.
2. Tang DC, DeVit M, Johnston SA. Genetic immunization is a simple method for eliciting an immune response. Nature 1992;356:152-4.
3. Ulmer JB, Donnelly JJ, Parker SE, et al. Heterologous protection against influenza by injection of DNA encoding a viral protein. Science 1993;259:1745-9.
4. Fynan EF, Robinson HL, Webster RG. Use of DNA encoding influenza hemagglutinin as an avian influenza vaccine. DNA Cell Biol 1993;12:785-9.
5. Montgomery DL, Shiver JW, Leander KR, et al. Heterologous and homologous protection against influenza A by DNA vaccination: optimization of DNA vectors. DNA Cell Biol 1993;12: 777-83.
6. Calarota S, Bratt G, Nordlund S, et al. Cellular cytotoxic response induced by DNA vaccination in HIV-1-infected patients. Lancet 1998;351:1320-5.
7. Fioretti D, Iurescia S, Fazio VM, Rinaldi M. DNA vaccines: developing new strategies against cancer. J Biomed Biotechnol 2010;2010:174378.
8. Martin JE, Pierson TC, Hubka S, et al. A West Nile virus DNA vaccine induces neutralizing antibody in healthy adults during a phase 1 clinical trial. J Infect Dis 2007;196:1732-40.
9. Vasan S, Schlesinger SJ, Chen Z, et al. Phase 1 safety and immunogenicity evaluation of ADMVA, a multigenic, modified vaccinia Ankara-HIV-1 B/C candidate vaccine. PLoS One 2010;5:e8816.
10. Einer-Jensen K, Delgado L, Lorenzen E, et al. Dual DNA vaccination of rainbow trout (Oncorhynchus mykiss) against two different rhabdoviruses, VHSV and IHNV, induces specific divalent protection. Vaccine 2009;27:1248-53.
11. Kutzler MA, Weiner DB. DNA vaccines: ready for prime time? Nat Rev Genet 2008;9:776-88.
12. Song JM, Kim YC, O E, et al. DNA vaccination in the skin using microneedles improves protection against influenza. Mol Ther 2012;20:1472-80.
13. Hung JT, Tsai YC, Lin WD, et al. Potent adjuvant effects of novel NKT stimulatory glycolipids on hemagglutinin based DNA vaccine for H5N1 influenza virus. Antiviral Res 2014;107:110-18.
14. Loudon PT, Yager EJ, Lynch DT, et al. GM-CSF increases mucosal and systemic immunogenicity of an H1N1 influenza DNA vaccine administered into the epidermis of non-human primates. PLoS One 2010;5:e11021.
15. Haensler J, Verdelet C, Sanchez V, et al. Intradermal DNA immunization by using jet-injectors in mice and monkeys. Vaccine 1999;17:628-38.
16. Yan J, Villarreal DO, Racine T, et al. Protective immunity to H7N9 influenza viruses elicited by synthetic DNA vaccine. Vaccine 2014;32:2833-42.
17. Chen MW, Liao HY, Huang Y, et al. Broadly neutralizing DNA vaccine with specific mutation alters the antigenicity and sugar-binding activities of influenza hemagglutinin. Proc Natl Acad Sci USA 2011;108:3510-15.
18. Kichaev G, Mendoza JM, Amante D, et al. Electroporation mediated DNA vaccination directly to a mucosal surface results in improved immune responses. Hum Vaccin Immunother 2013;9:2041-8.
19. Kumar P, Khanna M, Kumar B, et al. A conserved matrix epitope based DNA vaccine protects mice against influenza A virus challenge. Antiviral Res 2012;93:78-85.
20. Jazi MH, Dabaghian M, Tebianian M, et al. In vivo electroporation enhances immunogenicity and protection against influenza A virus challenge of an M2e-HSP70c DNA vaccine. Virus Res 2012;167:219-25.
21. Wang B, Yu H, Yang FR, et al. Protective efficacy of a broadly cross-reactive swine influenza DNA vaccine encoding M2e, cytotoxic T lymphocyte epitope and consensus H3 hemagglutinin. Virol J 2012;9:127.
22. Zhang L, Jia N, Li J, et al. Optimal designs of an HA-based DNA vaccine against H7 subtype influenza viruses. Hum Vaccin Immunother 2014;10:1949-58.
23. Guionie O, Niqueux E, Amelot M, et al. H5-based DNA constructs derived from selected highly pathogenic H5N1 avian influenza virus induce high levels of humoral antibodies in Muscovy ducks against low pathogenic viruses. Virol J 2014;11:74.
24. St PM, Barjesteh N, Brisbin JT, et al. Effects of ligands for Toll-like receptors 3, 4, and 21 as adjuvants on the immunogenicity of an avian influenza vaccine in chickens. Viral Immunol 2014;27:167-73.
25. Wibowo N, Hughes FK, Fairmaid EJ, et al. Protective efficacy of a bacterially produced modular capsomere presenting M2e from influenza: extending the potential of broadly cross-protecting epitopes. Vaccine 2014;32: 3651-5.
26. Chen JR, Yu YH, Tseng YC, et al. Vaccination of monoglycosylated hemagglutinin induces cross-strain protection against influenza virus infections. Proc Natl Acad Sci USA 2014;111:2476-81.
27. Smith LR, Wloch MK, Ye M, et al. Phase 1 clinical trials of the safety and immunogenicity of adjuvanted plasmid DNA vaccines encoding influenza A virus H5 hemagglutinin. Vaccine 2010;28: 2565-72.
28. Ledgerwood JE, Hu Z, Gordon IJ, et al. Influenza virus h5 DNA vaccination is immunogenic by intramuscular and intradermal routes in humans. Clin Vaccine Immunol 2012;19:1792-7.
29. Ledgerwood JE, Wei CJ, Hu Z, et al. DNA priming and influenza vaccine immunogenicity: two phase 1 open label randomised clinical trials. Lancet Infect Dis 2011;11:916-24.
30. Ledgerwood JE, Zephir K, Hu Z, et al. Prime-boost interval matters: a randomized phase 1 study to identify the minimum interval necessary to observe the H5 DNA influenza vaccine priming effect. J Infect Dis 2013;208:418-22.
31. Roos AK, Eriksson F, Timmons JA, et al. Skin electroporation: effects on transgene expression, DNA persistence and local tissue environment. PLoS One 2009;4:e7226.
32. Liu J, Kjeken R, Mathiesen I, Barouch DH. Recruitment of antigen-presenting cells to the site of inoculation and augmentation of human immunodeficiency virus type 1 DNA vaccine immunogenicity by in vivo electroporation. J Virol 2008;82: 5643-9.
33. Peng B, Zhao Y, Xu L, Xu Y. Electric pulses applied prior to intramuscular DNA vaccination greatly improve the vaccine immunogenicity. Vaccine 2007;25: 2064-73.
34. Suh H, Shin J, Kim YC. Microneedle patches for vaccine delivery. Clin Exp Vaccine Res 2014;3:42-9.
35. Yager EJ, Dean HJ, Fuller DH. Prospects for developing an effective particle-mediated DNA vaccine against influenza. Expert Rev Vaccines 2009;8:1205-20.
36. Logomasini MA, Stout RR, Marcinkoski R. Jet injection devices for the needle-free administration of compounds, vaccines, and other agents. Int J Pharm Compd 2013;17: 270-80.
37. Bagarazzi ML, Yan J, Morrow MP, et al. Immunotherapy against HPV16/ 18 generates potent TH1 and cytotoxic cellular immune responses. Sci Transl Med 2012;4:155ra138.
38. Vasan S, Hurley A, Schlesinger SJ, et al. In vivo electroporation enhances the immunogenicity of an HIV-1 DNA vaccine candidate in healthy volunteers. PLoS One 2011;6:e19252.
39. Low L, Mander A, McCann K, et al. DNA vaccination with electroporation induces increased antibody responses in patients with prostate cancer. Hum Gene Ther 2009;20:1269-78.
40. Churchyard GJ, Morgan C, Adams E, et al. A phase IIA randomized clinical trial of a multiclade HIV-1 DNA prime followed by a multiclade rAd5 HIV-1 vaccine boost in healthy adults (HVTN204). PLoS One 2011;6:e21225.
41. + T-cell responses after rAd5 boost in a randomized clinical trial. PLoS One 2013;8:e59340.
42. Brave A, Gudmundsdotter L, Sandstrom E, et al. Biodistribution, persistence and lack of integration of a multigene HIV vaccine delivered by needle-free intradermal injection and electroporation. Vaccine 2010;28:8203-9.
43. + T cells, T helper cells, and protective levels of antibody in humans by particle-mediated administration of a hepatitis B virus DNA vaccine. Vaccine 2000;19:764-78.
44. Drape RJ, Macklin MD, Barr LJ, et al. Epidermal DNA vaccine for influenza is immunogenic in humans. Vaccine 2006;24: 4475-81.
45. Hung IF, Levin Y, To KK, et al. Dose sparing intradermal trivalent influenza (2010/2011) vaccination overcomes reduced immunogenicity of the 2009 H1N1 strain. Vaccine 2012;30:6427-35.
46. Hallengard D, Brave A, Isaguliants M, et al. A combination of intradermal jet-injection and electroporation overcomes in vivo dose restriction of DNA vaccines. Genet Vaccines Ther 2012;10:5.
47. Alvarez B, Poderoso T, Alonso F, et al. Antigen targeting to APC: from mice to veterinary species. Dev Comp Immunol 2013;41:153-63.
48. Wang G, Pan L, Zhang Y. Approaches to improved targeting of DNA vaccines. Hum Vaccin 2011;7:1271-81.
49. Fredriksen AB, Sandlie I, Bogen B. Targeted DNA vaccines for enhanced induction of idiotype-specific B and T cells. Front Oncol 2012;2:154.
50. Kastenmuller W, Kastenmuller K, Kurts C, Seder RA. Dendritic cell-targeted vaccines - hope or hype? Nat Rev Immunol 2014;14: 705-11.
51. Kawamura H, Berzofsky JA. Enhancement of antigenic potency in vitro and immunogenicity in vivo by coupling the antigen to anti-immunoglobulin. J Immunol 1986;136:58-65.
52. Mjaaland S, Fossum S. Modulation of immune responses with monoclonal antibodies. I. Effects on regional lymph node morphology and on anti-hapten responses to haptenized monoclonal antibodies. Eur J Immunol 1990;20: 1457-61.
53. Skea DL, Douglas AR, Skehel JJ, Barber BH. The immunotargeting approach to adjuvant-independent immunization with influenza haemagglutinin. Vaccine 1993;11: 994-1002.
54. Snider DP, Segal DM. Targeted antigen presentation using crosslinked antibody heteroaggregates. J Immunol 1987;139: 1609-16.
55. Casten LA, Pierce SK. Receptor-mediated B cell antigen processing. Increased antigenicity of a globular protein covalently coupled to antibodies specific for B cell surface structures. J Immunol 1988;140: 404-10.
56. Lees A, Morris SC, Thyphronitis G, et al. Rapid stimulation of large specific antibody responses with conjugates of antigen and anti-IgD antibody. J Immunol 1990;145: 3594-600.
57. Baier G, Baier-Bitterlich G, Looney DJ, Altman A. Immunogenic targeting of recombinant peptide vaccines to human antigen-presenting cells by chimeric anti-HLA-DR and anti-surface immunoglobulin D antibody Fab fragments in vitro. J Virol 1995;69:2357-65.
58. Lunde E, Munthe LA, Vabo A, et al. Antibodies engineered with IgD specificity efficiently deliver integrated T-cell epitopes for antigen presentation by B cells. Nat Biotechnol 1999;17:670-5.
59. Biragyn A, Tani K, Grimm MC, et al. Genetic fusion of chemokines to a self tumor antigen induces protective, T-cell dependent antitumor immunity. Nat Biotechnol 1999;17:253-8.
60. Vander LB, Khan AA, Hackney JA, et al. Transcriptional programming of dendritic cells for enhanced MHC class II antigen presentation. Nat Immunol 2014;15:161-7.
61. +) dermal dendritic cells drive T helper 2 cell-mediated immunity. Immunity 2013;39:733-43.
62. Gao Y, Nish SA, Jiang R, et al. Control of T helper 2 responses by transcription factor IRF4-dependent dendritic cells. Immunity 2013;39:722-32.
63. Murakami R, Denda-Nagai K, Hashimoto S, et al. A unique dermal dendritic cell subset that skews the immune response toward Th2. PLoS One 2013;8: e73270.
64. + dendritic cell development. J Immunol 2013;191: 5993-6001.
65. Tamura T, Tailor P, Yamaoka K, et al. IFN regulatory factor-4 and -8 govern dendritic cell subset development and their functional diversity. J Immunol 2005;174:2573-81.
66. Idoyaga J, Lubkin A, Fiorese C, et al. Comparable T helper 1 (Th1) and CD8 T-cell immunity by targeting HIV gag p24 to CD8 dendritic cells within antibodies to Langerin, DEC205, and Clec9A. Proc Natl Acad Sci USA 2011;108: 2384-9.
67. Estrada A, McDermott MR, Underdown BJ, Snider DP. Intestinal immunization of mice with antigen conjugated to anti-MHC class II antibodies. Vaccine 1995;13:901-7.
68. Carayanniotis G, Barber BH. Adjuvant-free IgG responses induced with antigen coupled to antibodies against class II MHC. Nature 1987;327:59-61.
69. Grodeland G, Mjaaland S, Roux KH, et al. DNA vaccine that targets hemagglutinin to MHC class II molecules rapidly induces antibody-mediated protection against influenza. J Immunol 2013;191:3221-31.
70. Fredriksen AB, Sandlie I, Bogen B. DNA vaccines increase immunogenicity of idiotypic tumor antigen by targeting novel fusion proteins to antigen-presenting cells. Mol Ther 2006;13:776-85.
71. Grodeland G, Mjaaland S, Tunheim G, et al. The specificity of targeted vaccines for APC surface molecules influences the immune response phenotype. PLoS One 2013;8:e80008.
72. Castro FV, Tutt AL, White AL, et al. CD11c provides an effective immunotarget for the generation of both CD4 and CD8 T cell responses. Eur J Immunol 2008;38:2263-73.
73. Tjelle TE, Corthay A, Lunde E, et al. Monoclonal antibodies produced by muscle after plasmid injection and electroporation. Mol Ther 2004;9:328-36.
74. Fredriksen AB, Bogen B. Chemokine-idiotype fusion DNA vaccines are potentiated by bivalency and xenogeneic sequences. Blood 2007;110:1797-805.
75. + T cell-mediated protective and therapeutic antitumor immunity. J Immunol 2007;179:1381-8.
76. + T-cell responses. Blood 2006;107:4597-605.
77. Schjetne KW, Fredriksen AB, Bogen B. Delivery of antigen to CD40 induces protective immune responses against tumors. J Immunol 2007;178:4169-76.
78. Nchinda G, Kuroiwa J, Oks M, et al. The efficacy of DNA vaccination is enhanced in mice by targeting the encoded protein to dendritic cells. J Clin Invest 2008;118: 1427-36.
79. Froyland M, Ruffini PA, Thompson KM, et al. Targeted idiotype-fusion DNA vaccines for human multiple myeloma: preclinical testing. Eur J Haematol 2011;86:385-95.
80. Ruffini PA, Os A, Dolcetti R, et al. Targeted DNA vaccines eliciting crossreactive anti-idiotypic antibody responses against human B cell malignancies in mice. J Transl Med 2014;12:207.
81. Ruffini PA, Grodeland G, Fredriksen AB, Bogen B. Human chemokine MIP1alpha increases efficiency of targeted DNA fusion vaccines. Vaccine 2010;29:191-9.
82. Oynebraten I, Lovas TO, Thompson K, Bogen B. Generation of antibody-producing hybridomas following one single immunization with a targeted DNA vaccine. Scand J Immunol 2012;75(4):379-88.
83. Ruffini PA, Biragyn A, Coscia M, et al. Genetic fusions with viral chemokines target delivery of nonimmunogenic antigen to trigger antitumor immunity independent of chemotaxis. J Leukoc Biol 2004;76:77-85.
84. Lane PJL, McConnell FM, Schieven GL, et al. The role of class II molecules in human B cell activation. Association with phosphatidyl inositol turnover, protein tyrosine phosphorylation, and proliferation. J Immunol 1990;144:3684-92.
85. Subbarao K, Murphy BR, Fauci AS. Development of effective vaccines against pandemic influenza. Immunity 2006;24:5-9.
86. Staudt LM, Gerhard W. Generation of antibody diversity in the immune response of BALB/c mice to influenza virus hemagglutinin. I. Significant variation in repertoire expression between individual mice. J Exp Med 1983;157:687-704.
87. Caton AJ, Brownlee GG, Yewdell JW, Gerhard W. The antigenic structure of the influenza virus A/PR/8/34 hemagglutinin (H1 subtype). Cell 1982;31:417-27.
88. Dawood FS, Iuliano AD, Reed C, et al. Estimated global mortality associated with the first 12 months of 2009 pandemic influenza A H1N1 virus circulation: a modelling study. Lancet Infect Dis 2012;12:687-95.